Status:
NOT_YET_RECRUITING
Comparison of IPC Therapy as an Alternative or an Adjunct to MLD Within CDT for BCRL
Lead Sponsor:
Pamukkale University
Conditions:
Breast Cancer-Related Lymphedema
BCRL
Eligibility:
FEMALE
18-65 years
Phase:
NA
Brief Summary
Breast cancer is the most common cancer among women worldwide and lymphedema is one of its most significant complications. Breast cancer-related lymphedema (BCRL) may develop shortly after treatment o...
Detailed Description
Breast cancer is the most common malignancy among women worldwide and remains the leading cause of cancer-related mortality in women. Breast cancer-related lymphedema (BCRL) is one of the most importa...
Eligibility Criteria
Inclusion
- Female gender
- Patients aged 18-65 years
- Having a history of unilateral mastectomy and lymph node dissection at least one year ago due to breast cancer diagnosis.
- Having unilateral breast cancer-related upper extremity lymphedema (\>20% volume difference between the two upper extremities or \>2 cm difference in circumference at any measured point) according to the diagnostic criteria of the International Society of Lymphology (Committee 2023) for at least six months.
- Not having received lymphedema treatment or exercise therapy for the last six months
- Completing breast cancer primary treatment at least 6 months ago (except hormone therapy/aromatase inhibitors)
Exclusion
- Bilateral breast cancer
- Bilateral axillary lymph node dissection
- Metastatic breast cancer
- Receiving ongoing radiotherapy or chemotherapy
- Primary or bilateral lymphedema
- Having active cancer
- Presence of stage 3 lymphedema
- Uncontrolled serious systemic disease (cardiopulmonary diseases, arterial or venous diseases, renal dysfunction, uncontrolled hypertension or hypotension, cardiac arrhythmia, scleroderma, Sudek's atrophy).
- Current or recent (within the last 3 months) infection (cellulitis, lymphangitis) or deep venous thrombosis
- Presence of open wounds
- Using medications that may affect body fluid and electrolyte balance (diuretics, etc.).
- Individuals with serious mental and sensory problems
- Being pregnant
- Body mass index \>40 kg/m2
Key Trial Info
Start Date :
September 15 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT07154043
Start Date
September 15 2025
End Date
December 1 2026
Last Update
September 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pamukkale University
Denizli, Turkey (Türkiye)